Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
about
Targeting DNA Replication Stress for Cancer TherapyDistinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticityTherapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Broad and potent antiviral activity of the NAE inhibitor MLN4924.Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells.Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer TreatmentIdentification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma.Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.Cullin E3 Ligase Activity Is Required for Myoblast Differentiation.Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.Proteasome-associated deubiquitinases and cancer.The proteasome and proteasome inhibitors in multiple myeloma.Prospect of divergent roles for the CUL3 system in vascular endothelial cell function and angiogenesis.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Protein neddylation and its alterations in human cancers for targeted therapy.Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.High-Content Monitoring of Drug Effects in a 3D Spheroid Model.Neddylation mediates ventricular chamber maturation through repression of Hippo signaling.Proteasome inhibitors in cancer therapy.Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.Targeting CAND1 promotes caspase-8/RIP1-dependent apoptosis in liver cancer cells.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
P2860
Q26739923-1A0D14DF-B165-40A0-9257-B92CCE5EAB47Q28818350-F449D0E2-47DE-46B9-8DBC-CF93A0F27BCBQ33792598-7E96BECE-7F43-4498-BCEE-B2E3B5D29EACQ34521260-2C504BA6-24ED-4015-8743-E6151FF5BA21Q34543264-BA4DC5A3-5892-484E-BA1C-B847968E82F6Q36524801-13CA6DA8-6E3F-47FC-9BFA-842BBE2B5EF8Q37662370-F67DA4F9-FE86-4FE3-9270-82D0EC82B382Q38736706-A61D22F2-0B33-40B3-9AB6-2E679A1DCA11Q38972048-5726F9E1-ECA4-4809-928F-4A1987E775DCQ38988815-52F44B0D-E31A-4880-A524-02A5CD9413BCQ40303257-EA359CD3-CFDE-4BD3-86D2-6BEAC1CB900CQ40648639-9C319F41-53E1-4BC7-BDE4-D6494776C04AQ41971182-FE96C5FF-6F5C-48D5-8424-053C82F85115Q42292376-5ABD6F33-C535-4DD2-9E75-4390734C8825Q45931257-68F43DD4-59D4-45C5-B5DB-3C49C1E28787Q47095447-4FD23F37-673E-407A-B0FD-6315386E2E64Q47161331-F9B481AB-15A8-4F48-A802-B55045475C70Q47339695-B5D5D6D0-E126-4A12-8731-19DCE41ABBE3Q47692259-B7EA2A47-55EE-4091-93CA-CF7A779F95CFQ48216923-802B4DC4-AD08-42DA-B946-AFB906A1BBFCQ48538797-5908426A-8800-4E10-8CB6-46D2D1B8627FQ49456490-64010D70-EFBA-4291-BD5A-969022CF6580Q50099283-FB9D538C-632C-45AE-868F-5E2305F8EBECQ52720526-75DC0E28-E181-496B-9002-A664D372FED4Q53752929-27A6BF7D-E1A7-4A80-ABB9-9C21A2B15AAEQ54942210-64F0CAA8-DA38-442B-9598-ED99D0330A70Q55270698-C296FB10-64E8-4E53-8D50-29A0BD0BEE60Q55281964-D46EF8F4-CD2F-480D-81FA-FD2FEE9BF579
P2860
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@ast
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@en
type
label
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@ast
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@en
prefLabel
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@ast
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@en
P2093
P2860
P50
P1476
Phase I Study of the Novel Inv ...... Multiple Myeloma or Lymphoma.
@en
P2093
Allison J Berger
Andrzej J Jakubowiak
Bruce J Dezube
Daniel Lebovic
George Mulligan
Hélène M Faessel
Jatin J Shah
Kevin Kelly
Mitchell R Smith
Owen A O'Connor
P2860
P356
10.1158/1078-0432.CCR-15-1237
P407
P577
2015-11-11T00:00:00Z